Test Price
450 AED✅ Home Collection Available
CD61 Immunophenotyping by Flow Cytometry in UAE | AED 450 | DHA Licensed Lab
Executive Summary & Core Metrics
- 🩺 99.9% Diagnostic Sensitivity – ISO 9001:2015 accredited processing, validated against international hematopathology standards.
- 🏠 VIP Mobile Phlebotomy & Cold-Chain Home Collection – Available for peripheral blood samples from 8 AM to 11 PM daily; bone marrow aspiration requires hospital setting.
- 📞 Telephonic Post-Test Clinical Guidance – Free DHA-licensed specialist consultation for result interpretation.
- ✅ Insurance Direct Billing – Quick eligibility check via WhatsApp +971 54 548 8731.
Test Overview & Methodology
CD61 immunophenotyping by flow cytometry is the gold standard for identifying the megakaryocytic lineage in hematologic malignancies, enabling precise diagnosis of acute megakaryoblastic leukemia (AML‑M7) and monitoring of minimal residual disease. Our UAE‑based laboratory delivers rapid results with 99.9% sensitivity, backed by ISO 9001:2015 accreditation and DHA compliance.
| Feature | Our Test (Precision) | Closest Alternative (Hospital Lab) |
|---|---|---|
| Methodology | Multiparameter Flow Cytometry (CD61/Glycoprotein IIIa) with standardized EuroFlow panels | Conventional Flow Cytometry with limited markers |
| Diagnostic Sensitivity | 99.9% | ~95% |
| Turnaround Time | Same-day (sample collected by 9 AM) | 2-3 days |
| Accreditation | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | Local MOHAP only |
Physician Insight & Safety Protocols
“As a Specialist Diagnostic Radiology, I see CD61 immunophenotyping as a critical tool in confirming megakaryoblastic lineage. However, results must be correlated with bone marrow morphology and cytogenetics. Never alter medications without oncologist guidance.”
— Mr. Prabhakar Reddy Kalathoor, DHA License 61713011
⚠️ Medication Advisory
Do not discontinue prescribed medication without consulting your doctor. Abrupt changes can affect test interpretation and compromise your clinical management.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Severe thrombocytopenia (< 10,000/μL) without clinical supervision.
- Exclusion: Active, uncontrolled bleeding disorder or anticoagulant therapy that cannot be interrupted.
- Exclusion: Bone marrow transplant within 30 days (interferes with lineage assessment).
- Red Flag: Seek immediate medical attention if you experience uncontrolled bleeding, fever > 38.5°C, or sudden neurological symptoms before sample collection.
- Red Flag: If you develop petechiae, ecchymoses, or signs of sepsis, proceed to the nearest Emergency Department.
Patient FAQ & Clinical Guidance
1. What is CD61 immunophenotyping and why is it ordered?
CD61 immunophenotyping by flow cytometry precisely identifies platelet glycoprotein IIIa (CD61) expression on cells to diagnose acute megakaryoblastic leukemia and monitor therapy. This test is critical when AML‑M7 or a megakaryocytic lineage disorder is suspected based on morphology or clinical signs.
2. How should I prepare for the test and what is the procedure?
No fasting is required, but inform us of all medications. For peripheral blood, our certified phlebotomist will collect the sample at home using strict aseptic technique and immediately place it in cold‑chain transport. For bone marrow aspiration, the procedure is performed by a DHA‑licensed physician in a hospital setting under sterile conditions.
3. When will I receive my CD61 results and who will explain them?
Results are reported same‑day if the sample is collected by 9 AM. A complimentary tele‑consultation with a DHA‑licensed specialist is provided for clinical interpretation, ensuring you understand CD61 positivity, gating strategy, and correlation with your overall condition.
4. Can I take the test if I am on blood thinners?
If you are on anticoagulants, please inform our team. For peripheral blood collection, minor bruising may occur. For bone marrow aspiration, temporary cessation may be required under your physician’s guidance. Never stop any medication without professional advice.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Accreditation
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring secure handling of all patient information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing health data management and cybersecurity.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability – governing clinical testing safety and patient consent.
- DHA Facility License No. 1143 | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
- Home collection service for peripheral blood operates 8 AM‑11 PM, 7 days a week under DHA‑approved mobile phlebotomy protocols.
Clinical & Logistical Metadata
| Test Name | CD61 Immunophenotyping by Flow Cytometry |
| Price (AED) | 450 |
| Turnaround Time | Same-day (sample collected by 9 AM) |
| Sample Type / Matrix | Peripheral blood or Bone marrow aspirate |
| Methodology Used | Multiparameter Flow Cytometry (CD61/Glycoprotein IIIa) |
| ICD-10-CM Code | C94.0 (Acute megakaryoblastic leukemia) |
| LOINC Code | 58489-0 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians